Study of a new drug for advanced solid tumors with PIK3CA mutation
Treatments studied
This study tests a new drug (LAE118) alone or with other treatments for advanced solid tumors, especially cancers with a specific genetic change (PIK3CA). It aims to see if the drug is safe and effective, and may help if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced cancer that has spread or cannot be removed by surgery.
- You must have a PIK3CA mutation in your tumor, confirmed by a blood test.
- You must not have had prior treatment with a PI3K, AKT, or mTOR inhibitor unless you had to stop due to side effects.
- You must not have diabetes that requires medication.
- You must have adequate organ function and meet other health criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.